- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Increased Diabetes Risk Linked to INSTI Use in HIV Patients, Highlights study
Australia: A recent study published in Clinical Infectious Diseases has shown that the current use of integrase strand transfer inhibitors (INSTIs) compared to protease inhibitors or non-nucleotide reverse transcriptase inhibitors is linked to a higher risk of diabetes mellitus (DM) among individuals with HIV infection.
The prospective study from the RESPOND cohort consortium has revealed concerning findings regarding the use of integrase strand transfer inhibitors in individuals living with HIV. The research indicates that current usage of INSTIs is associated with an increased risk of developing diabetes, a link that appears to be influenced by changes in body mass index (BMI) and other factors.
Given that the use of integrase strand transfer inhibitors is linked to increased BMI and that BMI increases are associated with a higher risk of diabetes mellitus (DM), Dhanushi Rupasinghe, The Australian HIV Observational Database (AHOD), The Kirby Institute, UNSW Sydney, Australia, and colleagues investigated the relationship between INSTI and non-INSTI regimens, changes in BMI, and the risk of developing DM.
To investigate this relationship, the researchers included RESPOND participants who had CD4 counts, HIV RNA levels, and at least two BMI measurements during follow-up. Individuals with a history of diabetes mellitus were excluded. DM was defined based on a random blood glucose level of ≥ 11.1 mmol/L, an HbA1c of ≥ 6.5% (48 mmol/mol), the use of antidiabetic medications, or a clinical diagnosis reported by the site.
The researchers utilized Poisson regression to evaluate the association between the natural logarithm (ln) of time-updated BMI, current use of INSTI versus non-INSTI regimens, and their interactions concerning the risk of developing DM.
The following were the key findings of the study:
- Among 20,865 people with HIV included, most were male (74%) and White (73%). The baseline median age was 45 years with a median BMI of 24 kg/m2.
- There were 785 DM diagnoses with a crude rate of 0·73/100 PYFU.
- Ln(BMI) was strongly associated with DM (adjusted incidence rate ratio (aIRR) 16·54 per log increase).
- Current INSTI use is associated with increased DM risk (IRR 1·58) in univariate analyses, only partially attenuated when adjusted for variables including ln(BMI) (aIRR 1·48).
- There was no interaction between ln(BMI), INSTI and non-INSTI use, and DM.
Study limitations include the observational design of BMI assessments, the inability to account for other factors that may have influenced BMI, and the potential for underdiagnosing diabetes.
In the RESPOND study, the current use of INSTIs was linked to a higher risk of diabetes than non-INSTIs; however, this association was somewhat diminished when accounting for changes in BMI and other factors.
The researchers concluded, "The findings indicate that increases in BMI associated with INSTI use are linked to a similar rise in the risk of diabetes as BMI increases from other causes. Therefore, it would be prudent to interpret INSTI-related BMI changes in the context of diabetes risk similarly to other BMI increases."
Reference:
Rupasinghe, D., Law, M., Zangerle, R., Rauch, A., Tarr, P. E., Greenberg, L., Neesgaard, B., Jaschinski, N., De Wit, S., Wit, F., Monforte, A. D., Fontas, E., Castagna, A., Stecher, M., Brandes, V., Florence, E., Begovac, J., Mussini, C., Sönnerborg, A., . . . Petoumenos, K. Integrase strand transfer inhibitor (INSTI) related changes in BMI and risk of diabetes: A prospective study from the RESPOND cohort consortium. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae406
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751